Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET
Company Participants
Austin Murtagh – Director, Precision AQ
Greg Divis – CEO
Richard Kim – CCO
Jennifer Gudeman – SVP, Medical & Clinical Affairs
Tom McHugh – CFO
Conference Call Participants
Andrew Tsai – Jefferies
François Brisebois – Oppenheimer
Oren Livnat – H.C. Wainwright
Ami Fadia – Needham
David Amsellem – Piper Sandler
Operator
Good day everyone and welcome to today’s Avadel Pharmaceuticals 3Q 2024 Earnings Call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question-and-answer session. [Operator Instructions] Please note, this call is being recorded and I will be standing by in case you any assistance.
It is now my pleasure to turn the conference over to Austin Murtagh with Precision AQ.
Austin Murtagh
Good morning and thank you for joining us on our conference call to discuss Avadel’s third quarter 2024 results. As a reminder, before we begin, the following presentation includes several matters that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements.
These risks and uncertainties are described in Avadel’s public filings under the Exchange Act included in the Form 10-K for the year ended December 31st, 2023, which was filed on February 29th, 2024, and subsequent SEC filings.
Except as required by law, Avadel undertakes no obligation to update or revise any forward-looking statements contained in this presentation to reflect new information, future events, or otherwise.
On the call today are Greg Divis, Chief Executive Officer; Richard Kim, Chief Commercial Officer; and Tom McHugh, Chief Financial Officer; Dr. Jennifer Gudeman, Senior Vice President of Medical and
